RECRUITING

Low Dose Aspirin Alerts in High-Risk Pregnancies

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to assess the effect of an electronic health record (EHR) clinical decision support tool, also known as a best practice alert (BPA), on healthcare provider recommendations for low dose aspirin use in a high-risk pregnant patient population. The investigators hypothesize that the implementation of the EHR BPA tool will increase the healthcare provider's recommendation for low dose aspirin compared to current standard care.

Official Title

Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial

Quick Facts

Study Start:2023-06-19
Study Completion:2025-06-19
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05802940

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Receiving prenatal care within Geisinger
  2. * Initial prenatal visit prior to 28 weeks gestation
  3. * Determined to be high risk for preeclampsia based on the modified United States Preventive Services Task Force and American College of Obstetrics and Gynecology criteria (at least 1 high risk factor)
  1. * Not pregnant
  2. * No prenatal visit prior to 28 weeks gestation
  3. * Maternal-Fetal Medicine only visits
  4. * Not meeting the modified USPSTF high-risk criteria
  5. * Contraindication to aspirin, including allergy

Contacts and Locations

Study Contact

A. Dhanya Mackeen, MD, MPH
CONTACT
570-714-1099
admackeen@geisinger.edu
Amir Goren, PhD
CONTACT
570-214-4395
agoren@geisinger.edu

Principal Investigator

A. Dhanya Mackeen, MD, MPH
PRINCIPAL_INVESTIGATOR
Geisinger Clinic

Study Locations (Sites)

Geisinger Medical Center
Danville, Pennsylvania, 17822
United States

Collaborators and Investigators

Sponsor: Geisinger Clinic

  • A. Dhanya Mackeen, MD, MPH, PRINCIPAL_INVESTIGATOR, Geisinger Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-19
Study Completion Date2025-06-19

Study Record Updates

Study Start Date2023-06-19
Study Completion Date2025-06-19

Terms related to this study

Additional Relevant MeSH Terms

  • Preeclampsia
  • Aspirin
  • Clinical Decision Support Systems
  • Economics, Behavioral